Pancreatic Cancer
Conditions
Brief summary
Identifying the malignancy of pancreatic mass using endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is important for treatment decision-making and prognosis prediction. The sensitivity of EUS-FNA cytology specimens based on Papanicolaou (Pap) staining is low, which hampers accurate diagnosis of pancreatic mass. We assessed the diagnostic value of immunohistochemical (IHC) and immunofluorescence (IF) staining for methionyl-tRNA synthetase 1 (MARS1).
Detailed description
BACKGROUND / AIMS: The sensitivity of endoscopic ultrasound-guided aspiration cytology used to distinguish the pancreatic mass is low and clinical usefulness is not secured. The aim of this study was to evaluate clinical efficacy of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using pancreatic cancer related protein expressed only in pancreatic cancer. Hypothesis: The statistical significance between conventional staining method and MARS1 staining in the pancreatic cancer cells collected by endoscopic ultrasound-guided aspiration will be compared to prove the usefulness of the new staining method. Clinical study design: The expression of MARS1 in the pancreatic cancer cell line obtained by endoscopic ultrasound in patients suspected of having pancreatic cancer using Immunofluorescence or immunohistochemistry staining will be performed to differentiate the presence of the tumor. The sensitivity and specificity of the new staining method will be compared with the conventional staining method and its usefulness be confirmed.
Interventions
DIAGNOSTIC_TESTCytology staining
Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining. 1. conventional cytology staining method 2. new cytology staining method using antibody of methionyl-tRNA synthetase 1
Sponsors
Gangnam Severance Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
The conventional staining method and new staining method will be performed in cytology specimens obtained from same patient.
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with pancreatic cancer confirmed by imaging (CT, MRI, PET-CT) 2. Patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound 3. Patients who underwent surgical treatment with pancreatic cancer
Exclusion criteria
1. Minors under the age of 19, vulnerable subjects such as illiteracy 2. Excludes necrotic specimens 3. Samples with non-diagnostic cytology results and insufficient cells for further evaluation 4. Samples classified as neoplastic (benign or other)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The comparison of sensitivity between conventional staining method and new staining method | 1 year | The sensitivity of new staining method will be compared with the conventional Pap staining of endoscopic ultrasound-guided fine-needle aspiration cytology |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The evaluation of correlation index of staining at three type slides | 1 year | The correlation index of the new staining method will be evaluated at three type slides such as Thinprep, Surepath, and Direct smear. |
Countries
South Korea
Outcome results
None listed